124 related articles for article (PubMed ID: 22049464)
1. Antiserotonergic properties of terguride in blood vessels, platelets, and valvular interstitial cells.
Kekewska A; Görnemann T; Jantschak F; Glusa E; Pertz HH
J Pharmacol Exp Ther; 2012 Feb; 340(2):369-76. PubMed ID: 22049464
[TBL] [Abstract][Full Text] [Related]
2. The bulky N6 substituent of cabergoline is responsible for agonism of this drug at 5-hydroxytryptamine 5-HT2A and 5-HT2B receptors and thus is a determinant of valvular heart disease.
Kekewska A; Hübner H; Gmeiner P; Pertz HH
J Pharmacol Exp Ther; 2011 Jul; 338(1):381-91. PubMed ID: 21518772
[TBL] [Abstract][Full Text] [Related]
3. 5-HT
Chaturvedi S; Misra DP; Prasad N; Rastogi K; Singh H; Rai MK; Agarwal V
Int J Rheum Dis; 2018 Dec; 21(12):2128-2138. PubMed ID: 30207074
[TBL] [Abstract][Full Text] [Related]
4. Elevated cyclic stretch and serotonin result in altered aortic valve remodeling via a mechanosensitive 5-HT(2A) receptor-dependent pathway.
Balachandran K; Hussain S; Yap CH; Padala M; Chester AH; Yoganathan AP
Cardiovasc Pathol; 2012; 21(3):206-13. PubMed ID: 21865058
[TBL] [Abstract][Full Text] [Related]
5. Horse chestnut extract contracts bovine vessels and affects human platelet aggregation through 5-HT(2A) receptors: an in vitro study.
Felixsson E; Persson IA; Eriksson AC; Persson K
Phytother Res; 2010 Sep; 24(9):1297-301. PubMed ID: 20148408
[TBL] [Abstract][Full Text] [Related]
6. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology.
Adams JW; Ramirez J; Shi Y; Thomsen W; Frazer J; Morgan M; Edwards JE; Chen W; Teegarden BR; Xiong Y; Al-Shamma H; Behan DP; Connolly DT
J Pharmacol Exp Ther; 2009 Oct; 331(1):96-103. PubMed ID: 19628629
[TBL] [Abstract][Full Text] [Related]
7. Function and expression differences between ergot and non-ergot dopamine D2 agonists on heart valve interstitial cells.
Oana F; Onozuka H; Tsuchioka A; Suzuki T; Tanaka N; Kaidoh K; Hoyano Y; Hiratochi M; Kikuchi S; Takehana Y; Shibata N
J Heart Valve Dis; 2014 Mar; 23(2):246-52. PubMed ID: 25076559
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A receptors.
Görnemann T; Hübner H; Gmeiner P; Horowski R; Latté KP; Flieger M; Pertz HH
J Pharmacol Exp Ther; 2008 Mar; 324(3):1136-45. PubMed ID: 18096760
[TBL] [Abstract][Full Text] [Related]
9. Insurmountable antagonism of AT-1015, a 5-HT2 antagonist, on serotonin-induced endothelium-dependent relaxation in porcine coronary artery.
Rashid M; Nakazawa M; Nagatomo T
J Pharm Pharmacol; 2003 Jun; 55(6):827-32. PubMed ID: 12841944
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of 2-bromoterguride at human dopamine D2, porcine serotonin 5-hydroxytryptamine 2A, and α2C-adrenergic receptors, and its antipsychotic-like effects in rats.
Jantschak F; Brosda J; Franke RT; Fink H; Möller D; Hübner H; Gmeiner P; Pertz HH
J Pharmacol Exp Ther; 2013 Oct; 347(1):57-68. PubMed ID: 23863695
[TBL] [Abstract][Full Text] [Related]
11. Pergolide, terguride and N,N'-spacer-linked oligomers of both interact with 5-HT2A receptors of rat tail artery.
Kren V; Eich E; Pertz HH
Physiol Res; 2004; 53(1):35-43. PubMed ID: 14984312
[TBL] [Abstract][Full Text] [Related]
12. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
Newman-Tancredi A; Cussac D; Quentric Y; Touzard M; Verrièle L; Carpentier N; Millan MJ
J Pharmacol Exp Ther; 2002 Nov; 303(2):815-22. PubMed ID: 12388668
[TBL] [Abstract][Full Text] [Related]
13. Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitro.
Serebruany VL; El Mouelhi M; Pfannkuche HJ; Rose K; Marro M; Angiolillo DJ
Am J Ther; 2010; 17(6):543-52. PubMed ID: 19797939
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of 5-hydroxytryptamine-potentiated aggregation of human blood platelets by 5-hydroxytryptamine receptor-blocking agents.
Glusa E; Markwardt F
Biomed Biochim Acta; 1984; 43(2):215-20. PubMed ID: 6732757
[TBL] [Abstract][Full Text] [Related]
15. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.
Fitzgerald LW; Burn TC; Brown BS; Patterson JP; Corjay MH; Valentine PA; Sun JH; Link JR; Abbaszade I; Hollis JM; Largent BL; Hartig PR; Hollis GF; Meunier PC; Robichaud AJ; Robertson DW
Mol Pharmacol; 2000 Jan; 57(1):75-81. PubMed ID: 10617681
[TBL] [Abstract][Full Text] [Related]
16. Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats.
Dumitrascu R; Kulcke C; Königshoff M; Kouri F; Yang X; Morrell N; Ghofrani HA; Weissmann N; Reiter R; Seeger W; Grimminger F; Eickelberg O; Schermuly RT; Pullamsetti SS
Eur Respir J; 2011 May; 37(5):1104-18. PubMed ID: 20947677
[TBL] [Abstract][Full Text] [Related]
17. Proterguride, a highly potent dopamine receptor agonist promising for transdermal administration in Parkinson's disease: interactions with alpha(1)-, 5-HT(2)- and H(1)-receptors.
Schurad B; Horowski R; Jähnichen S; Görnemann T; Tack J; Pertz HH
Life Sci; 2006 Apr; 78(20):2358-64. PubMed ID: 16310806
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the contractile 5-hydroxytryptamine receptor in the renal artery of the normotensive rat.
Watts SW; Thompson JM
J Pharmacol Exp Ther; 2004 Apr; 309(1):165-72. PubMed ID: 14724222
[TBL] [Abstract][Full Text] [Related]
19. KMUP-1 inhibits pulmonary artery proliferation by targeting serotonin receptors/transporter and NO synthase, inactivating RhoA and suppressing AKT/ERK phosphorylation.
Chung HH; Dai ZK; Wu BN; Yeh JL; Chai CY; Chu KS; Liu CP; Chen IJ
Vascul Pharmacol; 2010; 53(5-6):239-49. PubMed ID: 20870034
[TBL] [Abstract][Full Text] [Related]
20. Vasodilator and vasoconstrictor responses induced by 5-hydroxytryptamine in the in situ blood autoperfused hindquarters of the anaesthetized rat.
Calama E; Fernández MM; Morán A; Martín ML; San Román L
Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):110-6. PubMed ID: 12122496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
